Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
SLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio.
| Ticker |
CPRX
|
| CIK | 0001369568 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL, 33134 |
| Website | catalystpharma.com |
| Phone | (305) 529-2522 |
| CEO | Patrick J. McEnany |
| Employees | 80 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's WhySLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio. Insmed Ends Brinsupri Development in Skin Disease Post Study FailureINSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues. SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in EczemaSanofi posts strong mid-stage results for lunsekimig in asthma and CRSwNP but a setback in atopic dermatitis clouds the broader clinical picture. AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye DiseaseAmgen's subcutaneous Tepezza hits phase III goals in thyroid eye disease, matches IV efficacy and offers faster dosing that could expand access. IBRX Responds to FDA Warning Over Misleading Cancer Drug ClaimsImmunityBio responds to an FDA warning over misleading Anktiva claims and outlines compliance fixes as strong sales growth and expansion efforts remain in focus. |